New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
07:32 EDTDNDNDendreon reports Q4 EPS (26c), consensus (56c)
Reports Q4 revenue $85.5M, consensus $82.88M. The company expects to reduce cost of goods sold to below 50% of net product revenue in the beginning of 3Q13. Expects to begin to see net benefits associated with the restructuring initiatives to begin to appear in financial results as early as 1H13, with full benefits realized in Q313. Says actively evaluating partnering strategies for European expansion; continuing to enroll patients in the sipuleucel-T European Union open-label study; expect a mid-2013 regulatory decision in Europe.
News For DNDN From The Last 14 Days
Check below for free stories on DNDN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 11, 2014
07:01 EDTDNDNDendreon: Immune responses enhanced when Provenge given after ADT
Dendreon Corporation announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE is given after androgen deprivation therapy in patients with biochemically-recurrent prostate cancer at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology Congress taking place from April 11-15, 2014 in Stockholm, Sweden.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use